

AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions and listings of claims in the application:

1-11. (Canceled)

12. (Currently Amended) A solid composition comprising:

a first component comprising 5-methyl-4-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and


a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about ~~0.8~~ 0.3% to about 15% of the first component.

13-14. (Canceled)

15. (Previously presented) The composition as claimed in claim 12, wherein the concentration of the second component is from about 1% to about 10% of the first component.
16. (Previously presented) The composition as claimed in claim 12, wherein the concentration of the second component is from about 1% to about 5% of the first component.
17. (Previously presented) The composition as claimed in claim 12, which comprises a first component and a second component in a form for rectal or oral administration.
- 18-19. (Canceled)
20. (Currently Amended) A method of treating an immunological disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4-trifluoromethyl-4-isoxazolecarboxanilide;
a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about ~~0.8~~ 0.3% to about 15% of the first component.

21. (Previously presented) The method of claim 20, wherein the composition produces a hyperadditive increase in the immunosuppressive effect.

22. (Previously presented) A method according to claim 20, wherein the immunological disease is an acute immunological disease.

23. (Previously presented) A method according to claim 22, wherein the acute immunological disease is sepsis, allergy, graft-versus-host reaction, or host-versus-graft reactions.


24. (Previously presented) A method according to claim 20, wherein the immunological disease is an autoimmune disease.

25. (Previously presented) A method according to claim 24, wherein the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis.

26. (Currently Amended) A method of treating a disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about ~~0.8~~ 0.3% to about 15% of the first component, and wherein the disease is atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, cystic fibrosis, colitis, or hepatic fibrosis.

27-28. (Canceled)

29. (Previously presented) A process for the preparation of a pharmaceutical composition of claim 12, which comprises processing components 1, 2, and 3 into a pharmaceutically acceptable form for administration.
30. (New) The composition as claimed in claim 12, wherein the concentration of the second component is from about 0.5% to about 15% of the first component.
31. (New) The composition as claimed in claim 12, wherein the concentration of the second component is from about 0.8% to about 15% of the first component.